Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-HER2-CAR-T cell (China Medical University)
- Development stage
- Unknown
- Lead developer
- China Medical University
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Anti-HER2-CAR-T cell therapy is an autologous cellular immunotherapy consisting of T cells genetically engineered to express a chimeric antigen receptor (CAR) that specifically targets the Human Epidermal Growth Factor Receptor 2 (HER2). HER2 is a tyrosine kinase receptor that is frequently overexpressed in various solid tumors, including breast, gastric, and lung cancers, where it promotes cell proliferation and survival. Upon administration, these engineered T cells recognize and bind to HER2-expressing tumor cells, leading to T-cell activation, the release of cytotoxic cytokines, and the direct lysis of the cancer cells. This specific program is being investigated by China Medical University in Phase 1 clinical trials for patients with HER2-positive locally advanced or metastatic solid tumors.
- Other names
- Anti-HER2-CAR-T Cells InjectionAnti-HER-2-CAR-T Cells InjectionAnti-HER 2-CAR-T Cells Injection
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on anti-HER2-CAR-T cell (China Medical University).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-HER2-CAR-T cell (China Medical University).